These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36316070)

  • 1. Performance of HPV testing, Pap smear and VIA in women attending cervical cancer screening in Kilimanjaro region, Northern Tanzania: a cross-sectional study nested in a cohort.
    Mremi A; Mchome B; Mlay J; Schledermann D; Blaakær J; Rasch V
    BMJ Open; 2022 Oct; 12(10):e064321. PubMed ID: 36316070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China.
    Zong LJ; Zhang YZ; Yang XS; Jiang J; Cui BX; Qiao YB; Li L; Jiang K; Zhang WJ; Kong BH; Shen K
    Asian Pac J Cancer Prev; 2015; 16(5):1907-12. PubMed ID: 25773843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
    Njue JK; Muturi M; Kamau L; Lwembe R
    Biomed Res Int; 2022; 2022():1930102. PubMed ID: 36164451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
    Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
    BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.
    Lindell M; Sanner K; Wikström I; Wilander E
    BJOG; 2012 Jan; 119(2):245-8. PubMed ID: 22017806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of visual inspection with acetic acid and human papillomavirus testing for detection of high-grade cervical lesions in HIV positive and HIV negative Tanzanian women.
    Dartell MA; Rasch V; Iftner T; Kahesa C; Mwaiselage JD; Junge J; Gernow A; Ejlersen SF; Munk C; Kjaer SK
    Int J Cancer; 2014 Aug; 135(4):896-904. PubMed ID: 24391021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability and feasibility of self-sampling and follow-up attendance after text message delivery of human papillomavirus results: A cross-sectional study nested in a cohort in rural Tanzania.
    Mremi A; Linde DS; Mchome B; Mlay J; Schledermann D; Blaakaer J; Rasch V
    Acta Obstet Gynecol Scand; 2021 Apr; 100(4):802-810. PubMed ID: 33555038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary high-risk HPV screening for cervical cancer in post-menopausal women.
    Gyllensten U; Gustavsson I; Lindell M; Wilander E
    Gynecol Oncol; 2012 May; 125(2):343-5. PubMed ID: 22293044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of high-risk human papillomavirus DNA detection between urine and cervical sample testing in women with abnormal Pap smears.
    Punyashthira A; Horthongkham N; Jaishuen A; Jareemit N; Achariyapota V
    J Obstet Gynaecol Res; 2022 Feb; 48(2):448-455. PubMed ID: 34750932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of visual inspection with acetic acid, Pap smear, or high-risk human papillomavirus testing in women living with HIV/AIDS for posttreatment cervical cancer screening: same tests, different priorities.
    Omenge Orang'o E; Liu T; Christoffersen-Deb A; Itsura P; Oguda J; Washington S; Chumba D; Pisharodi L; Cu-Uvin S; Rositch AF
    AIDS; 2017 Jan; 31(2):233-240. PubMed ID: 28002084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
    Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
    Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa.
    Hopkins KL; Jaffer M; Hlongwane KE; Otwombe K; Dietrich J; Cheyip M; Olivier J; Doherty T; Gray GE
    PLoS One; 2021; 16(7):e0255124. PubMed ID: 34329334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
    Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
    Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.